United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$233.85 USD
-2.10 (-0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $233.96 +0.11 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum C VGM
Price, Consensus and EPS Surprise
UTHR 233.85 -2.10(-0.89%)
Will UTHR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UTHR
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Other News for UTHR
Doctors perform first combined heart pump and pig kidney transplant surgery
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Noteworthy Wednesday Option Activity: UTHR, ACN, PI
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)